Skip to main content
OpenTrials

Clinical trial condition

Diffuse Large B-cell Lymphoma

Explore clinical trials studying Diffuse Large B-cell Lymphoma. Study availability and eligibility vary by location and protocol.

213 public trials 54 recruiting studies
Refine in advanced search Browse all conditions

Diffuse Large B-cell Lymphoma trial results

Completed

MabionCD20 Compared to MabThera in Lymphoma Patients

NCT02617485

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University Clinical Center Banja Luka Banja Luka, Bosnia and Herzegovina
  • University Clinical Center Sarajevo Sarajevo, Bosnia and Herzegovina
  • University Clinical Center Tuzla Tuzla, Bosnia and Herzegovina
  • General Hospital Zenica Zenica, Bosnia and Herzegovina
View all 35 locations
View Trial Details
Completed

Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL

NCT02399085

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • UCLA - David Geffen School of Medicine Los Angeles, California, United States
  • Cancer Care - Torrance Memorial Physician Network Redondo Beach, California, United States
  • Central Coast Medical Oncology Corporation Santa Maria, California, United States
View all 57 locations
View Trial Details
Completed

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT05338892

Conditions
Chronic Disease, Diffuse Large B-cell Lymphoma, Disease Attributes, +20 more
Locations
  • Regeneron Research Facility Graz, Austria
  • Regeneron Research Facility Caen, France
  • Regeneron Research Facility Paris, France
  • Regeneron Research Facility Pierre-Bénite, France
View Trial Details
Completed

Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

NCT01177397

Conditions
Adenocarcinoma, Astrocytoma, Blood Protein Disorders, +47 more
Locations
  • Cedars-Sinai Medical Center Los Angeles, California, United States
  • UCLA Neuro-Oncology Program Los Angeles, California, United States
  • University of California, San Francisco Hellen Diller Family Comprehensive Cancer Center San Francisco, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 16 locations
View Trial Details

Related conditions